Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Murat Tuncel

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|November 12, 2025
The 2025 ATA guidelines for differentiated thyroid Cancer - Ten years of professional debate and measured progressPetra Petranović Ovčariček, Frederik Anton Verburg, Bart de Keizer, et al.
Biomedicines|September 28, 2023
Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate CancerRie von Eyben, Manuela Andrea Hoffmann, Cigdem Soydal, et al.
Turkish Journal of Medical Sciences|June 18, 2019
Thyroid volumes and serum VEGF levels in dyslipidemic patients: effects of statin treatmentKadriye Aydın, Neşe Ersöz Gülçelik, Murat Tuncel, et al.
Radiology and Oncology|December 2, 2016
Prognosis estimation under the light of metabolic tumor parameters on initial FDG-PET/CT in patients with primary extranodal lymphomaKursat Okuyucu, Sukru Ozaydın, Engin Alagoz, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 17, 2022
To give or not to give? A critical appraisal of a clinical trial on radioiodine treatmentMurat Tuncel, Alexis Vrachimis, Alfredo Campenni, et al.
Cancers|February 25, 2023
Correction: von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. <i>Cancers</i> 2022, <i>14</i>, 5461Rie von Eyben, Daniel S Kapp, Manuela Andrea Hoffmann, et al.
Cancers|November 11, 2022
A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-AnalysisRie von Eyben, Daniel S Kapp, Manuela Andrea Hoffmann, et al.
Biomarkers in Medicine|March 14, 2025
Relationship between HE4 levels and metabolic parameters in PET of non-small cell lung cancer patientsYiğit Yilmaz, Mesut Melih Özercan, Burcu Ancin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 31, 2020
Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patientsCem Onal, Gokhan Ozyigit, Ozan Cem Guler, et al.
European Urology Oncology|February 9, 2022
Quality Goal for Salvage Treatment for Patients with Prostate Cancer at Prostate-specific Antigen RelapseRie von Eyben, Manuela Andrea Hoffmann, Daniel S Kapp, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
European Journal of Nuclear Medicine and Molecular Imaging|November 12, 2025
The 2025 ATA guidelines for differentiated thyroid Cancer - Ten years of professional debate and measured progressPetra Petranović Ovčariček, Frederik Anton Verburg, Bart de Keizer, et al.
Biomedicines|September 28, 2023
Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate CancerRie von Eyben, Manuela Andrea Hoffmann, Cigdem Soydal, et al.
Turkish Journal of Medical Sciences|June 18, 2019
Thyroid volumes and serum VEGF levels in dyslipidemic patients: effects of statin treatmentKadriye Aydın, Neşe Ersöz Gülçelik, Murat Tuncel, et al.
Radiology and Oncology|December 2, 2016
Prognosis estimation under the light of metabolic tumor parameters on initial FDG-PET/CT in patients with primary extranodal lymphomaKursat Okuyucu, Sukru Ozaydın, Engin Alagoz, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 17, 2022
To give or not to give? A critical appraisal of a clinical trial on radioiodine treatmentMurat Tuncel, Alexis Vrachimis, Alfredo Campenni, et al.
Cancers|February 25, 2023
Correction: von Eyben et al. A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-Analysis. <i>Cancers</i> 2022, <i>14</i>, 5461Rie von Eyben, Daniel S Kapp, Manuela Andrea Hoffmann, et al.
Cancers|November 11, 2022
A Risk Model for Patients with PSA-Only Recurrence (Biochemical Recurrence) Based on PSA and PSMA PET/CT: An Individual Patient Data Meta-AnalysisRie von Eyben, Daniel S Kapp, Manuela Andrea Hoffmann, et al.
Biomarkers in Medicine|March 14, 2025
Relationship between HE4 levels and metabolic parameters in PET of non-small cell lung cancer patientsYiğit Yilmaz, Mesut Melih Özercan, Burcu Ancin, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 31, 2020
Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patientsCem Onal, Gokhan Ozyigit, Ozan Cem Guler, et al.
European Urology Oncology|February 9, 2022
Quality Goal for Salvage Treatment for Patients with Prostate Cancer at Prostate-specific Antigen RelapseRie von Eyben, Manuela Andrea Hoffmann, Daniel S Kapp, et al.
Pageof 9